Ashvattha Therapeutics rallies $69m Series B

Ashvattha Therapeutics, a developer of novel hydroxyl dendrimer therapeutics, has secured $69 million in Series B financing.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this